Literature DB >> 34380744

N-Glycosylation Patterns Correlate with Hepatocellular Carcinoma Genetic Subtypes.

Andrew DelaCourt1, Alyson Black1, Peggi Angel1, Richard Drake1, Yujin Hoshida2, Amit Singal2, David Lewin3, Bachir Taouli4, Sara Lewis4, Myron Schwarz5, M Isabel Fiel6, Anand S Mehta7.   

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer deaths globally, and the incidence rate in the United States is increasing. Studies have identified inter- and intratumor heterogeneity as histologic and/or molecular subtypes/variants associated with response to certain molecular targeted therapies. Spatial HCC tissue profiling of N-linked glycosylation by matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) may serve as a new method to evaluate the tumor heterogeneity. Previous work has identified significant changes in the N-linked glycosylation of HCC tumors but has not accounted for the heterogeneous genetic and molecular nature of HCC. To determine the correlation between HCC-specific N-glycosylation changes and genetic/molecular tumor features, we profiled HCC tissue samples with MALDI-IMS and correlated the spatial N-glycosylation with a widely used HCC molecular classification (Hoshida subtypes). MALDI-IMS data displayed trends that could approximately distinguish between subtypes, with subtype 1 demonstrating significantly dysregulated N-glycosylation versus adjacent nontumor tissue. Although there were no individual N-glycan structures that could identify specific subtypes, trends emerged regarding the correlation of branched glycan expression to HCC as a whole and fucosylated glycan expression to subtype 1 tumors specifically. IMPLICATIONS: Correlating N-glycosylation to specific subtypes offers the specific detection of subtypes of HCC, which could both enhance early HCC sensitivity and guide targeted clinical therapies. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34380744      PMCID: PMC8802325          DOI: 10.1158/1541-7786.MCR-21-0348

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   6.333


  58 in total

1.  EDEM as an acceptor of terminally misfolded glycoproteins released from calnexin.

Authors:  Yukako Oda; Nobuko Hosokawa; Ikuo Wada; Kazuhiro Nagata
Journal:  Science       Date:  2003-02-28       Impact factor: 47.728

Review 2.  Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics.

Authors:  Naoyuki Taniguchi; Yasuhiko Kizuka
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

3.  Suppression of tumor growth and metastasis in Mgat5-deficient mice.

Authors:  M Granovsky; J Fata; J Pawling; W J Muller; R Khokha; J W Dennis
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

Review 4.  Cell surface protein glycosylation in cancer.

Authors:  Maja N Christiansen; Jenny Chik; Ling Lee; Merrina Anugraham; Jodie L Abrahams; Nicolle H Packer
Journal:  Proteomics       Date:  2014-03       Impact factor: 3.984

5.  Changes in the Glycosylation of Kininogen and the Development of a Kininogen-Based Algorithm for the Early Detection of HCC.

Authors:  Mengjun Wang; Miloslav Sanda; Mary Ann Comunale; Harmin Herrera; Charles Swindell; Yuko Kono; Amit G Singal; Jorge Marrero; Timothy Block; Radoslav Goldman; Anand Mehta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-02-21       Impact factor: 4.254

Review 6.  Glycosylation in cancer: mechanisms and clinical implications.

Authors:  Salomé S Pinho; Celso A Reis
Journal:  Nat Rev Cancer       Date:  2015-08-20       Impact factor: 60.716

7.  Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma.

Authors:  Mengjun Wang; Ronald E Long; Mary Ann Comunale; Omer Junaidi; Jorge Marrero; Adrian M Di Bisceglie; Timothy M Block; Anand S Mehta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05-19       Impact factor: 4.254

8.  Glycopeptides from the surface of control and virus-transformed cells.

Authors:  C A Buck; M C Glick; L Warren
Journal:  Science       Date:  1971-04-09       Impact factor: 47.728

9.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Andrew X Zhu; Yoon-Koo Kang; Chia-Jui Yen; Richard S Finn; Peter R Galle; Josep M Llovet; Eric Assenat; Giovanni Brandi; Marc Pracht; Ho Yeong Lim; Kun-Ming Rau; Kenta Motomura; Izumi Ohno; Philippe Merle; Bruno Daniele; Dong Bok Shin; Guido Gerken; Christophe Borg; Jean-Baptiste Hiriart; Takuji Okusaka; Manabu Morimoto; Yanzhi Hsu; Paolo B Abada; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2019-01-18       Impact factor: 41.316

10.  Imaging Mass Spectrometry and Lectin Analysis of N-Linked Glycans in Carbohydrate Antigen-Defined Pancreatic Cancer Tissues.

Authors:  Colin T McDowell; Zachary Klamer; Johnathan Hall; Connor A West; Luke Wisniewski; Thomas W Powers; Peggi M Angel; Anand S Mehta; David N Lewin; Brian B Haab; Richard R Drake
Journal:  Mol Cell Proteomics       Date:  2020-12-08       Impact factor: 5.911

View more
  4 in total

1.  Metabolic Links to Socioeconomic Stresses Uniquely Affecting Ancestry in Normal Breast Tissue at Risk for Breast Cancer.

Authors:  Denys Rujchanarong; Danielle Scott; Yeonhee Park; Sean Brown; Anand S Mehta; Richard Drake; George E Sandusky; Harikrishna Nakshatri; Peggi M Angel
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

2.  A Fucosylated Glycopeptide as a Candidate Biomarker for Early Diagnosis of NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation.

Authors:  Yu Lin; Jie Zhang; Ana Arroyo; Amit G Singal; Neehar D Parikh; David M Lubman
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

3.  GlycoFibroTyper: A Novel Method for the Glycan Analysis of IgG and the Development of a Biomarker Signature of Liver Fibrosis.

Authors:  Danielle A Scott; Mengjun Wang; Stephane Grauzam; Sarah Pippin; Alyson Black; Peggi M Angel; Richard R Drake; Stephen Castellino; Yuko Kono; Don C Rockey; Anand S Mehta
Journal:  Front Immunol       Date:  2022-02-07       Impact factor: 8.786

4.  Glycoprotein α-Subunit of Glucosidase II (GIIα) is a novel prognostic biomarker correlated with unfavorable outcome of urothelial carcinoma.

Authors:  Qiongqiong Lin; Lu Pei; Zhiguang Zhao; Xiaoping Zhuang; Haide Qin
Journal:  BMC Cancer       Date:  2022-07-25       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.